Kedrion Biopharma is an Italian biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating patients suffering from hemophilia, immune deficiencies and other serious illnesses.

Kedrion acts as a bridge between donors and the people who need treatments, and works on a global scale to expand the patients’ access to available treatments.

Headquartered in Italy, Kedrion Biopharma has a market presence in approximately 100 countries. In the field of plasma derivatives, it is the world’s 5th most important player and Italy’s 1st. The company employs more than 2300 people, over 1100 of whom are in Italy: over 50% of staff are under the age of 40 and women account for 40% of the workforce.

In Italy, Kedrion is partner of the National Health System, which it concretely supports in the pursuit of self-sufficiency in the supply of plasma-derived products. At the same time, the company offers its expertise and its efforts to communities and health systems all over the world to achieve the same goal, in the attempt to help improve the quality of life of people for patients with rare diseases.

Its state-of-the-art production facilities certified according to international GMPs (Good Manufacturing Practices) and based on FDA (Food and Drug Administration) requirements, its wide range of products and its constant commitment to research and development, represent the key factors of Kedrion’s success.